MMP20
MMP17, also known as Matrix Metallopeptidase 17, is a member of the matrix metalloproteinase (MMP) family, which is involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis.
Structure[edit]
MMP17 is a membrane-type matrix metalloproteinase (MT-MMP), which means it is anchored to the cell membrane. It is characterized by a transmembrane domain that allows it to be localized on the cell surface. The protein is synthesized as an inactive zymogen and requires proteolytic cleavage for activation.
Function[edit]
MMP17 plays a crucial role in the activation of other MMPs, such as MMP2, by cleaving their propeptide domains. This activation is essential for the degradation of the extracellular matrix components, which is a critical step in cell migration, invasion, and tissue remodeling. MMP17 is also involved in the shedding of cell surface molecules, which can influence cell signaling and interaction.
Clinical Significance[edit]
MMP17 has been implicated in various pathological conditions, including cancer, where it may contribute to tumor progression and metastasis by facilitating the invasion of cancer cells through the extracellular matrix. It is also involved in inflammatory diseases and has been studied in the context of osteoarthritis and rheumatoid arthritis.
Regulation[edit]
The activity of MMP17 is tightly regulated at multiple levels, including gene expression, zymogen activation, and inhibition by tissue inhibitors of metalloproteinases (TIMPs). Dysregulation of MMP17 activity can lead to excessive matrix degradation and is associated with various diseases.
Research Directions[edit]
Current research on MMP17 focuses on understanding its specific substrates and the pathways it influences. There is also interest in developing specific inhibitors that can modulate its activity for therapeutic purposes.
Also see[edit]
- Matrix metalloproteinase
- MMP2
- Tissue inhibitors of metalloproteinases
- Extracellular matrix
- Cancer metastasis
Template:Matrix Metalloproteinases
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian